Delivery of synthetic miR-181a mimic by transferrin (Tf)-conjugated nanoparticles (NP) enhanced miR-181a levels and inhibited RAS-dependent signaling pathways in AML. The gene discussed is TF; the disease is acute myeloid leukemia.